CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $512,430 | +52.7% | 18,600 | 0.0% | 0.10% | +41.9% |
| Q2 2023 | $335,544 | -1.4% | 18,600 | 0.0% | 0.07% | -42.6% |
| Q4 2022 | $340,380 | -3.6% | 18,600 | 0.0% | 0.13% | +50.0% |
| Q3 2022 | $353,000 | +0.6% | 18,600 | 0.0% | 0.09% | +11.7% |
| Q2 2022 | $351,000 | -14.0% | 18,600 | 0.0% | 0.08% | -2.5% |
| Q1 2022 | $408,000 | -22.0% | 18,600 | 0.0% | 0.08% | -12.2% |
| Q4 2021 | $523,000 | +42.1% | 18,600 | 0.0% | 0.09% | +34.3% |
| Q3 2021 | $368,000 | -5.2% | 18,600 | 0.0% | 0.07% | -10.7% |
| Q2 2021 | $388,000 | +26.8% | 18,600 | 0.0% | 0.08% | +15.4% |
| Q1 2021 | $306,000 | +16.3% | 18,600 | 0.0% | 0.06% | +8.3% |
| Q4 2020 | $263,000 | -15.4% | 18,600 | 0.0% | 0.06% | -29.4% |
| Q3 2020 | $311,000 | – | 18,600 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |